5:46 PM
 | 
Feb 21, 2014
 |  BC Extra  |  Company News

CHMP backs Teva's DuoResp Spiromax

EMA's CHMP backed approval of DuoResp Spiromax budesonide/formoterol from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to treat asthma and severe chronic obstructive pulmonary disease (COPD). DuoResp Spiromax is...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >